# FDA 483 - William C. Nabours, M.D. - January 16, 2026

Source: https://www.keypedia.com/records/483/william-c-nabours-md/b6ff2b56-8741-400a-8569-d14dff3f0438

> FDA 483 for William C. Nabours, M.D. on January 16, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: William C. Nabours, M.D.
- Inspection Date: 2026-01-16
- Product Type: drugs
- Office Name: New Orleans District Office
- Summary: An FDA inspection of William C. Nabours, M.D. in Lake Charles, LA, a clinical investigator, revealed significant deficiencies in conducting clinical trials. Observations included the enrollment of ineligible subjects who were immediate family members of study staff, violating protocol exclusion criteria. Additionally, the firm failed to maintain adequate and accurate case histories, specifically regarding the reporting of adverse events and concomitant medications in case report forms.

## Related Officers

- [Christopher M. Jeffers](https://www.keypedia.com/people/christopher-m-jeffers/327faaff-619a-4180-ab4c-b5f1b5ba84be)

Company: https://www.keypedia.com/companies/william-c-nabours-md/72c17a7d-1216-45f8-aff6-5f7fc615f98d

Office: https://www.keypedia.com/offices/new-orleans-district-office/95352142-b992-4e06-849d-d7483c0959ea